Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Beats on EPS, Stock Up 9.37%

Ligand Pharmaceuticals reported a strong earnings per share, significantly exceeding expectations, which led to a notable increase in stock price. The positive EPS surprise suggests effective cost management or strong product performance. However, the lack of revenue data and guidance leaves some uncertainty about future performance.